IL319012A - Heterocyclic sik inhibitors - Google Patents

Heterocyclic sik inhibitors

Info

Publication number
IL319012A
IL319012A IL319012A IL31901225A IL319012A IL 319012 A IL319012 A IL 319012A IL 319012 A IL319012 A IL 319012A IL 31901225 A IL31901225 A IL 31901225A IL 319012 A IL319012 A IL 319012A
Authority
IL
Israel
Prior art keywords
heterocyclic
sik inhibitors
sik
inhibitors
heterocyclic sik
Prior art date
Application number
IL319012A
Other languages
Hebrew (he)
Inventor
Andrea Nicole Bootsma
David Christopher Ebner
Daniel Wei-Shung Kung
Matthew Alexander Perry
Daniel Copley Schmitt
Joseph Walter Strohbach
Atli Thorarensen
Original Assignee
Pfizer
Andrea Nicole Bootsma
David Christopher Ebner
Kung Daniel Wei Shung
Matthew Alexander Perry
Daniel Copley Schmitt
Joseph Walter Strohbach
Atli Thorarensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Andrea Nicole Bootsma, David Christopher Ebner, Kung Daniel Wei Shung, Matthew Alexander Perry, Daniel Copley Schmitt, Joseph Walter Strohbach, Atli Thorarensen filed Critical Pfizer
Publication of IL319012A publication Critical patent/IL319012A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL319012A 2022-09-21 2023-09-18 Heterocyclic sik inhibitors IL319012A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263376480P 2022-09-21 2022-09-21
PCT/IB2023/059215 WO2024062360A1 (en) 2022-09-21 2023-09-18 Heterocyclic sik inhibitors

Publications (1)

Publication Number Publication Date
IL319012A true IL319012A (en) 2025-04-01

Family

ID=88197059

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319012A IL319012A (en) 2022-09-21 2023-09-18 Heterocyclic sik inhibitors

Country Status (19)

Country Link
US (1) US20240124450A1 (en)
EP (1) EP4590675B1 (en)
JP (1) JP7826572B2 (en)
KR (1) KR20250070082A (en)
CN (1) CN119948025A (en)
AR (1) AR130531A1 (en)
AU (1) AU2023346248A1 (en)
CA (1) CA3268028A1 (en)
CL (1) CL2025000479A1 (en)
CO (1) CO2025003311A2 (en)
CR (1) CR20250098A (en)
DO (1) DOP2025000069A (en)
FI (1) FI4590675T3 (en)
IL (1) IL319012A (en)
MX (1) MX2025003324A (en)
PE (1) PE20251177A1 (en)
PY (1) PY2375863A (en)
TW (1) TW202421625A (en)
WO (1) WO2024062360A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3103304A1 (en) 2018-06-15 2019-12-19 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2025232877A1 (en) * 2024-05-10 2025-11-13 Insilico Medicine Ip Limited Salt-inducible kinases (sik) inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT901786E (en) 1997-08-11 2007-08-07 Pfizer Prod Inc Solid pharmaceutical dispersions with enhanced bioavailability
CA2722418C (en) * 2008-05-13 2013-09-17 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
EP2993169B1 (en) 2009-11-17 2017-12-20 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
LT2925757T (en) 2012-11-19 2017-12-27 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9260426B2 (en) * 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
JP6441830B2 (en) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted 2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid (cyano-methyl) -amide inhibitors of cathepsin C
GB2522226A (en) 2014-01-17 2015-07-22 Agency Science Tech & Res Heteroaryl alkyne derivatives and uses thereof
TWI763722B (en) 2016-10-14 2022-05-11 美商林伯士拉克許米公司 Tyk2 inhibitors and uses thereof
CN110869756B (en) 2017-07-10 2023-10-27 新东工业株式会社 Surface characteristic evaluation method, surface characteristic evaluation device, and surface characteristic evaluation system
WO2019105886A1 (en) * 2017-12-02 2019-06-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
CA3089762A1 (en) 2018-01-29 2019-08-01 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
CA3103304A1 (en) * 2018-06-15 2019-12-19 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
JP7576552B2 (en) 2019-01-18 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド Imidazo[1,2-a]pyridinyl derivatives and their use in the treatment of diseases - Patents.com
GB201907616D0 (en) * 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
GB201907558D0 (en) * 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2020249096A1 (en) * 2019-06-14 2020-12-17 南京明德新药研发有限公司 Fused ring compound as fgfr and vegfr dual inhibitor
EP4003992A1 (en) 2019-07-24 2022-06-01 Merck Patent GmbH 4-(imidazo[1,2-a]pyridin-3-yl) -pyrimidine derivatives
GB201915831D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
AR120982A1 (en) 2020-01-06 2022-04-06 Syngenta Crop Protection Ag HETEROCYCLIC DERIVATIVES ACTIVE AS PESTICIDES WITH SUBSTITUENTS CONTAINING SULFUR
AU2021320860A1 (en) * 2020-08-05 2023-02-23 The General Hospital Corporation Salt inducible kinase inhibitors
EP4284801A4 (en) * 2021-02-01 2025-04-23 Janssen Biotech, Inc. Small molecule inhibitors of salt-inducible kinases
US20240174662A1 (en) * 2021-02-01 2024-05-30 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
CN115197208A (en) * 2021-04-01 2022-10-18 江苏恒瑞医药股份有限公司 Heteroaryl compound, preparation method and application thereof in medicine
CN113336751A (en) * 2021-05-31 2021-09-03 南京谷睿生物科技有限公司 High-efficiency salt-induced kinase inhibitor and preparation method thereof
CN115448881A (en) * 2021-06-09 2022-12-09 江苏恒瑞医药股份有限公司 Heteroaryl compound, preparation method and application thereof in medicine
CN118119619A (en) * 2021-10-18 2024-05-31 上海美悦生物科技发展有限公司 SIK inhibitor and composition, preparation method and application thereof
EP4737443A1 (en) * 2023-05-24 2026-05-06 Tanabe Pharma Corporation Salt-inducible kinase inhibitory compound and pharmaceutical composition containing same

Also Published As

Publication number Publication date
DOP2025000069A (en) 2025-04-30
JP2025532626A (en) 2025-10-01
JP7826572B2 (en) 2026-03-09
US20240124450A1 (en) 2024-04-18
CL2025000479A1 (en) 2025-07-11
AU2023346248A1 (en) 2025-03-06
FI4590675T3 (en) 2026-07-22
CN119948025A (en) 2025-05-06
CR20250098A (en) 2025-05-05
EP4590675B1 (en) 2026-05-27
MX2025003324A (en) 2025-05-02
PY2375863A (en) 2024-05-20
TW202421625A (en) 2024-06-01
KR20250070082A (en) 2025-05-20
CA3268028A1 (en) 2024-03-28
PE20251177A1 (en) 2025-04-23
AR130531A1 (en) 2024-12-18
EP4590675A1 (en) 2025-07-30
WO2024062360A1 (en) 2024-03-28
CO2025003311A2 (en) 2025-04-16

Similar Documents

Publication Publication Date Title
IL318647A (en) Heterocyclic compounds and uses thereof
IL315099A (en) Heterocyclic compounds and uses thereof
IL316285A (en) Heterocyclic compounds and uses thereof
ES3065238T3 (en) Heterocyclic pad4 inhibitors
IL279173A (en) New heterocyclic compounds as monoacylglycerol lipase inhibitors
IL280762A (en) New heterocyclic compounds as monoacylglycerol lipase inhibitors
IL308421A (en) Substituted heterocyclic compounds
IL290508A (en) Heterocyclic compounds as kinase inhibitors
IL289594A (en) New heterocyclic monoacylglycerol lipase (magl) inhibitors
IL299664A (en) Heterocyclic compounds
ZA202212631B (en) Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
IL314049A (en) Parp7 inhibitors
IL288936A (en) Heterocyclic monoacylglycerol lipase (magl) inhibitors
IL308422A (en) Substituted heterocyclic compounds
IL320185A (en) Heterocyclic compound
ZA202110352B (en) New heterocyclic compounds
CA3268028A1 (en) Heterocyclic sik inhibitors
EP4457224A4 (en) Heterocyclic compounds
EP4404927A4 (en) Methanogen inhibitors
PT3924351T (en) Formulations comprising heterocyclic protein kinase inhibitors
IL320814A (en) Heterocyclic compound and use thereof
EP4561975A4 (en) Fto inhibitors
IL313412A (en) Heterocyclic compounds as kit kinase inhibitors
SMT202500406T1 (en) Tead inhibitors
EP4263533C0 (en) Erap inhibitors